Search

• GSK's Promacta® (eltrombopag) receives FDA approval of an additional indication

  Media

  New first-in-class treatment option for this previously treated SAA patient population

  https://www.gsk.com/en-gb/media/press-releases/gsks-promacta-eltrombopag-receives-fda-approval-of-an-additional-indication/

  First published: 26 August 2014

• Malaria vaccine candidate has demonstrated efficacy over 3-4 years of follow-up

  Media

  Final results from a large-scale Phase III trial of the RTS,S malaria vaccine candidate published today in The Lancet.

  https://www.gsk.com/en-gb/media/press-releases/malaria-vaccine-candidate-has-demonstrated-efficacy-over-3-4-years-of-follow-up/

  First published: 24 April 2015

• GSK’s malaria candidate vaccine, Mosquirix™ (RTS,S), receives positive opinion from European regulators for the prevention of malaria in young children in sub-Saharan Africa

  Media

  GSK announced that the CHMP of EMA has adopted a positive scientific opinion for its malaria candidate vaccine Mosquirix.

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-malaria-candidate-vaccine-mosquirix-rts-s-receives-positive-opinion-from-european-regulators-for-the-prevention-of-malaria-in-young-children-in-sub-saharan-africa/

  First published: 24 July 2015

• GSK submits regulatory application for chlorhexidine gel for the prevention of umbilical cord infections in newborn babies

  Media

  GSK announced it's submitted an application to EMA for antiseptic chlorhexidine gel for the prevention omphalitis in newborn babies.

  https://www.gsk.com/en-gb/media/press-releases/gsk-submits-regulatory-application-for-chlorhexidine-gel-for-the-prevention-of-umbilical-cord-infections-in-newborn-babies/

  First published: 12 October 2015

• GSK announces positive new data comparing Incruse® Ellipta® to tiotropium and glycopyrronium in patients with COPD

  Media

  GSK announced positive results from comparing umeclidinium to two available bronchodilator treatments when used by patients with COPD.

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-new-data-comparing-incruse-ellipta-to-tiotropium-and-glycopyrronium-in-patients-with-copd/

  First published: 20 October 2015

• GSK’s candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over

  Media

  GSK today announced that the second pivotal phase III study of its candidate vaccine Shingrix™ successfully met its primary objective

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-candidate-shingles-vaccine-demonstrates-90-efficacy-against-shingles-in-people-70-years-of-age-and-over/

  First published: 27 October 2015

• GSK presents new data for once-weekly Tanzeum/Eperzan (albiglutide) showing blood glucose lowering up to three years in type 2 diabetes

  Media

  Data from four randomised phase III studies show that patients on albiglutide, continued to show blood glucose lowering at three years.

  https://www.gsk.com/en-gb/media/press-releases/gsk-presents-new-data-for-once-weekly-tanzeumeperzan-albiglutide-showing-blood-glucose-lowering-up-to-three-years-in-type-2-diabetes/

  First published: 14 June 2014

• GSK’s regulatory application for Shingrix for the prevention of shingles in at-risk adults aged 18 and over accepted for review by China National Medical Products Administration

  Media

  Shingrix already approved in China for adults aged 50 years and over.

  https://www.gsk.com/en-gb/media/press-releases/regulatory-application-for-shingrix-for-the-prevention-of-shingles-adults-aged-18-and-over-accepted-for-review-in-china/

  First published: 06 February 2024

• GSK responds to latest report from the O’Neill Review on antibiotic resistance

  Media

  It is essential that we find new ways to increase antibiotics R&D and create a future pipeline of new treatments.

  https://www.gsk.com/en-gb/media/press-releases/gsk-responds-to-latest-report-from-the-o-neill-review-on-antibiotic-resistance/

  First published: 14 May 2015

• GSK submits Japan regulatory application for mepolizumab in severe eosinophilic asthma

  Media

  GSK announced application to the Japanese MHLW for mepolizumab as add-on maintenance treatment for patients with severe eosinophilic asthma

  https://www.gsk.com/en-gb/media/press-releases/gsk-submits-japan-regulatory-application-for-mepolizumab-in-severe-eosinophilic-asthma/

  First published: 22 May 2015